Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Plerixafor plus G-CSF permits more to mobilise but at a cost

    • 12 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Delgado E, LeMaistre CF, Bachier C, Smith B, López-González G, Hougham M, Kaleel S, Shaughnessy P.Cost analysis of mobilization and autologous transplantation in patients who received AMD 3100 after failing standard mobilization. 50th Annual Meeting and Exposition of the American Society of Hematology: abstr. 2151, 7 Dec 2008. Available from: URL: http://www.hematology.org

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Plerixafor plus G-CSF permits more to mobilise but at a cost. Pharmacoecon. Outcomes News 569, 8 (2009). https://doi.org/10.2165/00151234-200905690-00018

    Download citation

    Keywords

    • Mobilisation Data
    • Autologous Transplant
    • Inpatient Cost
    • Median Total Cost
    • Plerixafor